Furthermore, specifically designed trials are needed to dissect the consequences of altered sex steroid levels (e.g., in hypogonadism) from those arising from increased (or decreased) FSH levels on similarly affected target organs, and to better clarify the impact on, for example, the GH/IGF-1 axis. The gene discussed is BRD2; the disease is hypogonadism.